ASH: Auto-HCT Not Beneficial for Mantle Cell Lymphoma With Undetectable Residual Disease
Overall survival no better for those receiving autologous HCT plus maintenance rituximab versus rituximab alone
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.